The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 16, Issue 2, 1999, Pages 142-146

  Ammari, F ^b   Davies, M J ^a   Koppiker, N ^b   Gregory, R ^b   Burden, A C ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Asian; Gliclazide; Insulin; Proinsulin; Sulphonylurea; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; GLUCOSE; INSULIN; PROINSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; SOUTH ASIA;

EID: 0032757846     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00025.x     Document Type: Article

References (28)

1. 1 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
2. 2 Temple RC, Carrington CA, Luzio SD, owens DR, Schneider AE, Sobey WJ et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989; i: 293-295.
3. 3 Davies MJ, Rayman G, Day JL, Gray IP, Hales CN. Impaired glucose tolerance, a condition of defective beta cell function and insulin deficiency. Diabetic Med 1992; 9: 1A.
4. 4 Davies MJ, Metcalfe J, Gray IP, Day JL, Hales CN. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed Type 2 diabetes mellitus. Diabetic Med 1993; 10: 305-312.
5. 5 Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Eng J Med 1992; 326: 22-29.
6. 6 Saad MF, Kahn SE, Nelson RG. Disproportionately elevated proinsulin in Pima Indians with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990; 70: 1247-1253.
7. 7 Gorden P, Hendricks CM, Roth J. Circulating proinsulin-like component in man: increased proportion in hypoinsulinaemic states. Diabetologia 1974; 10: 469-474.
8. 8 Mako ME, Starr JI, Rubenstein AH. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977; 63: 865-869.
9. 9 Williams DRR, Byrne C, Clark PMS, Cox L, Day NE, Hales CN et al. Raised proinsulin as an early indicator of β cell function. Br J Med 1991; 303: 95-96.
10. 10 Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988; 31: 355-360.
11. 11 Tillil H, Frank BH, Pekar AH, Broelsch C, Rubenstein AH, Polonsky KS. Hypoglycaemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites. Endocrinology 1990; 127: 2418-2422.
12. 12 Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR et al. Biosynthetic human proinsulin; review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992; 5: 666-692.
13. 13 Davies MJ, Grenfell A, Metcalfe J, Gray IP, Day JL, Hales CN. Improved beta cell function following dietary treatment in non-insulin-dependent diabetes mellitus (NIDDM). Diabetic Med 1994; 11: 71-78.
14. 14 Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y. Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 1989; 38: 262-266.
15. 15 Fineberg SE, Schneider SH. Glipizide versus tolbutamide an open trial. Effects on insulin secretory patterns and glucose concentrations. Diabetologia 1980; 18: 49-54.
16. 16 Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part I. Drugs 1981; 22: 211-245.
17. 17 Cerasi E, Efendic S, Thornqvist C, Luft R. Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects. Acta Endocrinol 1979; 91: 282-293.
18. 18 Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus Diabetic Med 1994; 11: 293-298.
19. 19 Mather HM, Keen H. The Southall Diabetes survey: prevalence of known diabetes in Asians and Europeans. Br Med J 1985; 291: 1081-1084.
20. 20 Gelding SV, Skinner E, Niththyananthan R, Robinson S, Gray IP, Johnston DG. Insulin resistance in Asian but not Caucasian relatives of Type 2 diabetic patients. Diabetic Med 1992; 9: A 30.
21. 21 Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS et al. The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
22. 22 McKeigue PM, Marmot MG. Mortality from coronary heart disease in asian communities in London. Br Med J 1988; 297: 903.
23. 23 Davies MJ, Ammari F, Gjural J, Burden AC. Screening for diabetes in the Indoasian population in the UK. Diabetic Med 1996; 13: S42.
24. 24 World Health. Organisation. Study Group. Diabetes Mellitus. WHO Tech Rep Ser 1985 No 727.
25. 25 Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP et al. Sensitive and specific and two-site immunoradiometric assays for human insulin, proinsulin. 65-66 split and 32-33 split proinsulins. Biochem J 1989; 260: 535-541.
26. 26 Sturgess NC, Ashford MLJ, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985; 2: 474-475.
27. 27 Hausman L, Schumann G, Kaffarnik H. Insulin and proinsulin secretion following intravenous administration of Tolbutamide, Glisoxepide and Glibenclamide. Arzneimittel-Forschung 1978; 1: 83-86.
28. 28 Kamakura S, Iwato Y, Kuguya T, Shiraishi I, Matsuda A, Saito T. Elevated ratio of summed serum proinsulin response after oral glucose load in type II diabetes decreases following sulfonylurea treatment. Diabetes Res Clin Pract 1995; 29: 107-112.